Recent developments
Financial and structural shifts
Q1 highlighted contrasting corporate positions. SABIC Q1 2026 results showed higher EBITDA amid portfolio exits and an agreement to enable 3.5 million tyres/year in Saudi Arabia. BASF’s Verbund remains efficient yet energy‑vulnerable, prompting restructuring. Trinseo faced expiring waivers and possible asset sales. Momentive named Bob Waitt CCO to steer commercial strategy.
Asia R&D and capacity
Asia concentrated new elastomer capabilities. ARLANXEO’s Innovation Center Asia expanded compounding, testing and battery‑application labs beside its EPDM/HNBR lines, while PRC‑produced EPDM under Keltan KSA makes it the exclusive seller. Evonik opened the Asia PAthletic Center and doubled regional PA12 capacity via its Shanghai polymerization reactor. Arkema at CHINAPLAS 2026 and Sinopec at the China International Plastics & Rubber Industry Exhibition highlighted elastomers and integrated solutions.
Materials and applications
Medical and consumer elastomers advanced. Mitsubishi Chemical’s ZELAS TPS adoption for iP‑TEC cell‑culture tubing supports closed‑loop handling, sterilization compatibility and superior iPS cell proliferation versus PVC. Elkem introduced eco‑designed PURESIL elastomers using a biobased alkane carrier for sensory performance in beauty formulations. Evonik and Arkema emphasised PA12/PEBA solutions for footwear and mobility, with additive offerings targeting PFAS‑free processing and recycling efficiency.
Standards and feedstocks
Regulation and inputs evolved. For injectables, stricter expectations for elastomeric closures reaffirm functional suitability (USP 382), E&L, and CCI, stressing lifecycle responsibility and risks from format migration and multi‑market filings. On solvents, Rompetrol’s Vega Ploieşti began 60%‑purity hexane production, enabling higher extraction rates for edible oils and industrial uses including adhesives and rubber, with 150 t/day capacity and export‑oriented supply.